Retroviral transduction of human CD34+ umbilical cord blood progenitor cells with a mutated dihydrofolate reductase cDNA.
Umbilical cord blood cells (UCB) have become a major target population for experimental and clinical studies using transfer of genes involved in inborn enzymatic diseases. Cord blood contains hematopoietic progenitor cells at a high frequency, and expanding these cells ex vivo generates sufficient numbers of hematopoietic precursors for transplantation into adults, e.g., as supportive treatment. As clinical reports about retroviral transduction into UCB cells have not been as encouraging as the first preclinical data, we have established a retroviral transduction system that allows expansion and selection of hematopoietic progenitor cells from UCB. CD34-enriched UCB cells were transduced with a retroviral vector encoding a mutated dihydrofolate reductase cDNA that confers MTX resistance. We observed increased resistance to MTX in transduced granulocyte macrophage-colony forming units (CFU-GM) after co-culture of CD34+ UCB cells with the virus-producing cell line, or after incubation with virus-containing supernatant. The supernatant-based transduction protocol included a prestimulation with recombinant interleukin-1 (rhIL-1), rhkit-ligand, and rhIL-3 to increase the percentage of cells in S phase to greater than 50%. Using this protocol we measured a 72-fold expansion of CFU-GM and a 2.5-fold selective advantage of transduced versus nontransduced progenitor cells after exposure to low-dose methotrexate in liquid culture. Polymerase chain reaction analysis revealed integration of proviral DNA into the majority of transduced colonies before and after ex vivo expansion. The retroviral vector and transduction protocol reported here provides an experimental system for selection and expansion of retrovirally transduced progenitor/stem cells from UCB that may help improve the efficiency of current clinical gene therapy strategies.
Flasshove
M
M
James Ewing Laboratory of Developmental Hematopoiesis of the Cell Biology and Genetics Program, Sloan-Kettering Institute for Cancer Research, New York, NY 10021, USA.
Banerjee
D
D
Leonard
J P
JP
Mineishi
S
S
Li
M X
MX
Bertino
J R
JR
Moore
M A
MA
D018952:Antigens, CD34 / Q000276:immunology*; D018076:DNA, Complementary / Q000235:genetics*; D004351:Drug Resistance; D005312:Fetal Blood / Q000166:cytology*; D005493:Folic Acid Antagonists / Q000494:pharmacology; D018014:Gene Transfer Techniques; D005822:Genetic Vectors / Q000235:genetics; D006412:Hematopoietic Stem Cells / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008727:Methotrexate / Q000494:pharmacology; D009154:Mutation; D011533:Proviruses / Q000235:genetics; D012190:Retroviridae / Q000235:genetics; D016196:S Phase / Q000187:drug effects; D013762:Tetrahydrofolate Dehydrogenase / Q000235:genetics*
D018952:Antigens, CD34; D018076:DNA, Complementary; D005493:Folic Acid Antagonists; D013762:Tetrahydrofolate Dehydrogenase; D008727:Methotrexate